Gelteq (GELS) vs Kiora Pharmaceuticals (KPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GELS | KPRX |
|---|---|---|
| Share price | $0.2701 | $0.7202 |
| Market cap | $3.11M | $3.19M |
| 1-day change | -3.74% | -12.28% |
| YTD return | — | -63.44% |
| 1-year return | — | -61.49% |
| 5-year return | — | -99.87% |
| EPS (TTM) | $-0.44 | $-2.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-6.65M | $-10.84M |
| 52-week high | $2.01 | $2.91 |
| 52-week low | $0.255 | $0.72 |
| Distance from 52-week high | -86.56% | -75.25% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1566.20% |
| Average volume | 2.85M | 35.23K |
| Shares outstanding | 11.51M | 4.42M |
| Employees | 7 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Gelteq
GELS stock →Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
GELS vs KPRX FAQ
Which is bigger, Gelteq or Kiora Pharmaceuticals?
Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.11M for Gelteq (GELS).
Are Gelteq and Kiora Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.